• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Biotech: Down for the Count

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-03-01-2001
Volume 0
Issue 0

Stirling, UK-Scotia became the first public UK biotechnology company to seek protection from creditors after the European Medicines Evaluation Agency rejected Foscan (temoporfin), the anticancer agent on which its fortunes were pinned.

Related Videos
Related Content